These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 22672003

  • 1. Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    O'Shea JG.
    Clin Exp Optom; 2012 Sep; 95(5):541-3. PubMed ID: 22672003
    [No Abstract] [Full Text] [Related]

  • 2. Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    Aujla JS.
    Clin Exp Optom; 2012 Sep; 95(5):538-40. PubMed ID: 22621684
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration?
    Micieli JA.
    Can J Ophthalmol; 2011 Dec; 46(6):549-51. PubMed ID: 22153646
    [No Abstract] [Full Text] [Related]

  • 5. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J.
    JAMA; 2014 Jul 02; 312(1):23-4. PubMed ID: 24860863
    [No Abstract] [Full Text] [Related]

  • 6. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC.
    Clin Exp Ophthalmol; 2010 May 02; 38(4):333-4. PubMed ID: 20642588
    [No Abstract] [Full Text] [Related]

  • 7. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N.
    BMJ; 2012 May 09; 344():e3275. PubMed ID: 22573655
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, Whitehead M, Gill SS.
    Ophthalmology; 2012 Aug 09; 119(8):1604-8. PubMed ID: 22717458
    [Abstract] [Full Text] [Related]

  • 10. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP.
    J Eval Clin Pract; 2012 Apr 09; 18(2):247-55. PubMed ID: 20846318
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab for the treatment of neovascular age-related macular degeneration.
    Pitlick JM, Vecera KF, Barnes KN, Reski JW, Forinash AB.
    Ann Pharmacother; 2012 Feb 09; 46(2):290-6. PubMed ID: 22274144
    [Abstract] [Full Text] [Related]

  • 12. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.
    Jiang S, Park C, Barner JC.
    J Clin Pharm Ther; 2014 Jun 09; 39(3):234-9. PubMed ID: 24635444
    [Abstract] [Full Text] [Related]

  • 13. Shanghai eye treatment outbreak: bevacizumab therapy for AMD in China.
    Huang HB, Pan Y, Liu T.
    Clin Exp Optom; 2013 Jan 09; 96(1):106-8. PubMed ID: 23051067
    [No Abstract] [Full Text] [Related]

  • 14. Why using Avastin for eye disease is so difficult.
    Torjesen I.
    BMJ; 2012 May 01; 344():e3012. PubMed ID: 22549057
    [No Abstract] [Full Text] [Related]

  • 15. Bevacizumab: a new hope?
    Madhusudhana KC, Newsom RS.
    Eye (Lond); 2009 Sep 01; 23(9):1755-7. PubMed ID: 19741717
    [No Abstract] [Full Text] [Related]

  • 16. Intravitreal avastin: the low cost alternative to lucentis?
    Rosenfeld PJ.
    Am J Ophthalmol; 2006 Jul 01; 142(1):141-3. PubMed ID: 16815262
    [No Abstract] [Full Text] [Related]

  • 17. Comparing ranibizumab with bevacizumab.
    Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S.
    Ophthalmology; 2011 Mar 01; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA.
    Br J Ophthalmol; 2015 Feb 01; 99(2):141-6. PubMed ID: 25271911
    [Abstract] [Full Text] [Related]

  • 19. Debate on the various anti-vascular endothelial growth factor drugs.
    Khalili MR, Hosseini H.
    Indian J Ophthalmol; 2008 Feb 01; 56(3):255-6; author reply 256. PubMed ID: 18417837
    [No Abstract] [Full Text] [Related]

  • 20. [Anti-VEGF: one drug for different conditions?].
    Cohen SY, Massin P, Souied E.
    J Fr Ophtalmol; 2013 Jan 01; 36(1):2-4. PubMed ID: 23290491
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.